Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 84   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2009  |  Volume : 1  |  Issue : 1  |  Page : 9-14

Metastatic renal cell carcinoma: A guide to therapy based on current evidence

Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Correspondence Address:
Toni K Choueiri
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Harvard Medical School, 44 Binney Street, Dana 1230, Boston, MA 02115
Login to access the Email id

DOI: 10.4103/0974-7796.48781

Rights and Permissions

Metastatic renal cell carcinoma (RCC) was, until recently, considered a challenging disease to treat with few therapeutic options of limited benefit. The past few years have seen spectacular advances in the treatment of this disease based on understanding the molecular pathways behind tumor growth and angiogenesis. This progress has led to the development of targeted therapies such as the receptor tyrosine kinase inhibitors sunitinib and sorafenib, the anti-vascular endothelial growth factor antibody bevacizumab, and a class of rapamycin analogues that includes temsirolimus and everolimus that have each demonstrated clinical efficacy in patients with metastatic RCC. The goal of this manuscript is to review the current evidence based on large randomized trials and propose a rationale paradigm for the treatment of this disease.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded887    
    Comments [Add]    

Recommend this journal